CORRECTION: Spectral AI Schedules 2024 Fourth Quarter and Full Year Financial Results and Conference Call
Spectral AI (NASDAQ: MDAI) has issued a correction to its earlier announcement regarding the scheduling of its 2024 fourth quarter and full year financial results. The company will now release its financial results on Thursday, March 27, 2025, after market close, followed by a conference call at 5:00 pm Eastern Time.
Spectral AI, known for its DeepView® System which received FDA Breakthrough Device Designation in 2018, specializes in using multi-spectral imaging and AI algorithms to predict burn healing potential. Investors can participate in the conference call by dialing 844-481-3008 (U.S.) or 412-317-1892 (International). A simultaneous webcast will be available through the Events & Presentations section of the company's Investor Relations webpage.
Spectral AI (NASDAQ: MDAI) ha emesso una correzione al suo precedente annuncio riguardante la programmazione dei risultati finanziari del quarto trimestre e dell'intero anno 2024. L'azienda rilascerà ora i suoi risultati finanziari giovedì 27 marzo 2025, dopo la chiusura del mercato, seguiti da una conferenza telefonica alle 17:00 ora orientale.
Spectral AI, conosciuta per il suo DeepView® System, che ha ricevuto la Designazione di Dispositivo Innovativo dalla FDA nel 2018, si specializza nell'uso di imaging multispettrale e algoritmi AI per prevedere il potenziale di guarigione delle ustioni. Gli investitori possono partecipare alla conferenza telefonica componendo il numero 844-481-3008 (U.S.) o 412-317-1892 (Internazionale). Sarà disponibile un webcast simultaneo attraverso la sezione Eventi e Presentazioni della pagina web delle Relazioni con gli Investitori della società.
Spectral AI (NASDAQ: MDAI) ha emitido una corrección a su anuncio anterior sobre la programación de los resultados financieros del cuarto trimestre y del año completo 2024. La compañía ahora publicará sus resultados financieros el jueves 27 de marzo de 2025, después del cierre del mercado, seguido de una llamada de conferencia a las 5:00 p. m. hora del Este.
Spectral AI, conocida por su DeepView® System, que recibió la Designación de Dispositivo Innovador de la FDA en 2018, se especializa en el uso de imágenes multiespectrales y algoritmos de IA para predecir el potencial de curación de quemaduras. Los inversores pueden participar en la llamada de conferencia marcando el 844-481-3008 (EE. UU.) o el 412-317-1892 (Internacional). Se dispondrá de una transmisión simultánea a través de la sección de Eventos y Presentaciones de la página web de Relaciones con Inversores de la compañía.
스펙트럴 AI (NASDAQ: MDAI)는 2024년 4분기 및 전체 연도 재무 결과 발표 일정에 대한 이전 발표를 수정했습니다. 회사는 이제 2025년 3월 27일 목요일에 시장 종료 후 재무 결과를 발표하고, 동부 표준시 기준 오후 5시에 컨퍼런스 콜을 진행합니다.
스펙트럴 AI는 2018년에 FDA 혁신 장치 지정을 받은 DeepView® System으로 알려져 있으며, 다중 스펙트럼 이미징 및 AI 알고리즘을 사용하여 화상 치유 가능성을 예측하는 전문 기업입니다. 투자자들은 844-481-3008 (미국) 또는 412-317-1892 (국제)로 전화를 걸어 컨퍼런스 콜에 참여할 수 있습니다. 회사의 투자자 관계 웹페이지의 이벤트 및 프레젠테이션 섹션을 통해 동시에 웹캐스트도 제공됩니다.
Spectral AI (NASDAQ: MDAI) a émis une correction à son annonce précédente concernant la programmation des résultats financiers du quatrième trimestre et de l'année complète 2024. La société publiera désormais ses résultats financiers le jeudi 27 mars 2025, après la fermeture du marché, suivis d'une conférence téléphonique à 17h00, heure de l'Est.
Spectral AI, connue pour son DeepView® System, qui a reçu la désignation de Dispositif Innovant par la FDA en 2018, se spécialise dans l'utilisation d'images multispectrales et d'algorithmes d'IA pour prédire le potentiel de guérison des brûlures. Les investisseurs peuvent participer à la conférence téléphonique en composant le 844-481-3008 (États-Unis) ou le 412-317-1892 (International). Un webinaire simultané sera disponible via la section Événements et Présentations de la page des Relations Investisseurs de l'entreprise.
Spectral AI (NASDAQ: MDAI) hat eine Korrektur zu seiner früheren Ankündigung bezüglich der Terminierung der Finanzzahlen für das vierte Quartal und das gesamte Jahr 2024 veröffentlicht. Das Unternehmen wird seine Finanzzahlen nun am Donnerstag, den 27. März 2025, nach Börsenschluss veröffentlichen, gefolgt von einer Telefonkonferenz um 17:00 Uhr Eastern Time.
Spectral AI, bekannt für sein DeepView® System, das 2018 von der FDA die Auszeichnung als Durchbruchgerät erhielt, spezialisiert sich auf die Verwendung von multispektraler Bildgebung und KI-Algorithmen zur Vorhersage des Heilungspotenzials von Verbrennungen. Investoren können an der Telefonkonferenz teilnehmen, indem sie 844-481-3008 (USA) oder 412-317-1892 (International) anrufen. Ein gleichzeitiger Webcast wird über den Bereich Veranstaltungen und Präsentationen der Investor-Relations-Webseite des Unternehmens verfügbar sein.
- None.
- None.
DALLAS, Feb. 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Spectral AI, Inc. (NASDAQ: MDAI), the reporting date of the financial results for the fourth quarter was incorrectly stated, and has been amended. The corrected release follows:
Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 on Thursday, March 27, 2025 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time to discuss the results.
Investors interested in participating in the live call can dial:
- 844-481-3008 - U.S.
- 412-317-1892 - International
A simultaneous webcast of the call may be accessed online from the Events & Presentations section of the Investor Relations page of the Company’s website at https://investors.spectral-ai.com/news-events/events.
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView® is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView®, visit www.spectral-ai.com.
Forward Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,”
“may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.
These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward- looking statements.
Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward- looking statements.
For Media and Investor Relations, please contact:
David Kugelman
Atlanta Capital Partners LLC
(866) 692-6847 Toll Free – U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
Email: dk@atlcp.com
FAQ
When will Spectral AI (MDAI) release its Q4 2024 financial results?
How can investors join Spectral AI's (MDAI) Q4 2024 earnings call?
What is Spectral AI's (MDAI) DeepView® System breakthrough designation status?
Where can investors access the webcast of MDAI's Q4 2024 earnings call?
What technology does Spectral AI's (MDAI) DeepView® System use?
